Opinion
Standard-of-care therapy in lung cancer: Be open to new ideas
- Author:
- Mark G. Kris, MD
Publish date: March 15, 2023
There’s no doubt that our outcomes are better for patients, but it’s much harder to make the best choice and I think there’s more pressure on us...
Opinion
Postop RT: Meaningful survival improvement in N2 lung cancer
- Author:
- Mark G. Kris, MD
Publish date: February 24, 2023
“When you have patients with N2 disease, after the completion of systemic therapies, think about the use of PORT and get the advice of a radiation...
Opinion
ctDNA shows promise for assessing lung cancer treatment response
- Author:
- Mark G. Kris, MD
Publish date: February 14, 2022
These are critical therapies because they are given with the intention of improving the chance for cure.
Opinion
Alleviating chemo-related nausea is a huge unmet need
- Author:
- Mark G. Kris, MD
Publish date: February 3, 2022
We control nausea in only half of the patients who receive cisplatin in 2022. That is a huge issue.
Article
Highlights in Non–Small Cell Lung Cancer From ASCO 2020
- Author:
- Mark G. Kris, MD
Publish date: June 22, 2020
Dr. Mark Kris reports on key studies in NSCLC from ASCO 2020, including the practice-changing ADAURA trial, results on an antibody‒...